Role of Consolidative Stereotactic Body Radiation Therapy in Oligoresistant/Oligoprogressive Pulmonary Parenchymal Metastases

Figures & data

Table 1 Patient and Treatment Characteristics

Characteristics (N=19)	Median (IQR) or n (%)
Age, year	65 (62–71)
Sex (male/female)	17/2
KPS	70 (60–80)
Tumor diameter, cm	2.2 (1.2–3.7)
Imaging used for disease staging
PET/CT only	10 (52.6)
CT	19 (100.0)
Biopsy	19 (100.0)
Tumor Diameter (modified from AJCC)
≤3 cm	12 (63.2)
>3 cm - ≤5 cm	6 (31.6)
>5 cm - ≤7 cm	-
>7 cm	1 (5.3)
Tumor Sites
Lung cancer	14 (73.7)
GIS	3 (15.8)
GUS	2 (10.5)
Pet/CT Fusion for planning	4 (21.1)
Dose, Gy	60.0 (55.0–60.0)
BED10, Gy	169.0 (115.5–180.0)
BED3, Gy	460.0 (364.0–460.0)
Fraction	3 (3–5)

Abbreviations: IQR, Interquartile range; CT, computed tomography; MRI, magnetic resonance imaging; PET, positron emission tomography; NSCLC, non-small-cell lung cancer; SCLC, small cell lung cancer; BED₁₀, biologically effective dose at an α/β ratio of 10.

Table 2 Local Control, Regional Control, and Survival Analysis

	Univariate Analysis		Multivariate Analysis
Local Control (N=19)
Tumor Diameter (cm)	Crude Hazard Ratio (95% CI)	p-value	Adjusted Hazard Ratio (95% CI)	p-value
≤2	1.0	-	1.0	-
>2	2.0 (0.6–4.6)	0.337	1.9 (0.5–7.2)	0.588
Response on PET-CT (first PET-CT response, 3 months after treatment)	Crude Hazard Ratio (95% CI)	p-value	Adjusted Hazard Ratio (95% CI)	p-value
Complete	1.0	-	1.0	-
Partial	1.9 (0.9–4.1)	0.612	1.9 (0.7–5.8)	0.991
Regional Control (N=19) (regions of the lung and mediastinal lymph regions)
Tumor Diameter (cm)	Crude Hazard Ratio (95% CI)	p-value	Adjusted Hazard Ratio (95% CI)	p-value
≤2	1.0	-	1.0	-
>2	1.4 (0.5–3.7)	0.513	1.2 (0.4–3.3)	0.278
Response on PET/CT	Crude Hazard Ratio (95% CI)	p-value	Adjusted Hazard Ratio (95% CI)	p value
Complete	1.0	-	1.0	-
Partial	2.3 (1.0–5.2)	0.684	2.3 (0.9–5.6)	0.995
Overall Survival (N=19)
Tumor Diameter, cm	Crude Hazard Ratio (95% CI)	p-value	Adjusted Hazard Ratio (95% CI)	p-value
≤2	1.0	-	1.0	-
>2	2.0 (0.6–4.6)	0.337	1.8 (0.7–4.9)	0.549
Distant Metastasis	Crude Hazard Ratio (95% CI)	p-value	Adjusted Hazard Ratio (95% CI)	p-value
No	1.0	-	1.0	-
Yes	1.1 (0.5–2.6)	0.506	1.0 (0.4–2.4)	0.812
Regional Recurrence	Crude Hazard Ratio (95% CI)	p-value	Adjusted Hazard Ratio (95% CI)	p-value
No	1.0	-	1.0	-
Yes	1.1 (0.4–3.1)	0.822	1.1 (0.4–3.3)	0.708

Abbreviations: BED₁₀, biologically effective dose at an α/β ratio of 10; SCC, squamous cell carcinoma; adeno, adenocarcinoma; PET-CT, positron emission tomography-computed tomography.

Figure 1 Overall Survival-Local Recurrence Relationship (months).

Figure 2 Progression-Free Survival -Local Recurrence Relationship (months).

Table 3 Cause of Death

Class	Frequency	Percent	Valid Percent	Cumulative Percent
Death of lung disease	1	5.3	5.3	5.3
Metastasis	2	10.5	10.5	15.8
Other	3	15.8	15.8	31.6
Alive	13	68.4	68.4	100.0
Total	19	100.0	100.0

Table 4 The Final Conditions of the Patients

Class	Frequency	Percent	Valid Percent	Cumulative Percent
Alive, disease-free	10	52.6	52.6	52.6
Alive with disease	3	15.8	15.8	68.4
Exitus	6	31.6	31.6	100.0
Total	19	100.0	100.0